Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Myeloproliferative Disorders 2Stomach Neoplasms 1Recurrence 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Eosinophilia 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

pembrolizumab 2MLN 8237 2pemigatinib 1liposomal doxorubicin 1cabiralizumab 1Nivolumab 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Malignancies × pemigatinib × Clear all
NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated
10 enrolled 9 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡